Global Cancer Biological Therapy Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Therapy Type;

Gene Therapy, Monoclonal Antibody Therapy, Vaccines Therapy, Targeted Drug Therapy, Bio Chemotherapy, Cancer Growth Blockers, and Others

By Cancer Type;

Pancreatic Cancer, Blood Cancer, Lung Cancer, Colorectal Cancer, and Others

By Route of Administration;

Intravenous, Subcutaneous, Intrathecal, and Intramuscular

By End User;

Hospitals, Speciality Clinics, Cancer Research Centres, and Others

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn113713520 Published Date: June, 2025 Updated Date: July, 2025

Cancer Biological Therapy Market Overview

Cancer Biological Therapy Market (USD Million)

Cancer Biological Therapy Market was valued at USD 87,456.61 million in the year 2024. The size of this market is expected to increase to USD 127,052.58 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 5.5%.


Global Cancer Biological Therapy Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 5.5 %


Study Period2025 - 2031
Base Year2024
CAGR (%)5.5 %
Market Size (2024)USD 87,456.61 Million
Market Size (2031)USD 127,052.58 Million
Market ConcentrationMedium
Report Pages352
87,456.61
2024
127,052.58
2031

Major Players

  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi, Pfizer Inc.
  • GSK plc
  • Novartis AG
  • Bayer AG
  • Lilly
  • Merck & Co., Inc.
  • Sun Pharmaceutical Industries Ltd.

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Cancer Biological Therapy Market

Fragmented - Highly competitive market without dominant players


The Cancer Biological Therapy Market continues to gain momentum as biologics emerge as a cornerstone of modern oncology treatment. Unlike traditional therapies, these approaches engage the immune system to selectively attack cancer cells. Currently, over 60% of new oncology drugs under development are biologics, reflecting a major transition toward targeted, immune-based solutions.

Shift Toward Precision and Safety
The demand for biological therapies is rising due to their superior precision and reduced toxicity. These therapies offer a more focused approach, minimizing harm to healthy tissues. Today, around 48% of oncology-related prescriptions are linked to biologics, demonstrating their growing dominance in treatment protocols and improved patient adherence.

Advances Driving Market Growth
Breakthroughs in monoclonal antibodies, cytokine therapies, and gene-based treatments are transforming the market landscape. With more than 35% of current candidates driven by biomarker-based platforms, innovation is helping deliver more personalized cancer care, enhancing both treatment success and patient survival outcomes.

Supportive Ecosystem and Patient Demand
With improved safety profiles and strong clinical efficacy, biologics are receiving favorable regulatory backing. Patient demand for effective and less harmful therapies is also rising. As a result, nearly 42% of current cancer trial enrollments involve biologics, further validating their expanding role in the treatment ecosystem.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Therapy Type
    2. Market Snapshot, By Cancer Type
    3. Market Snapshot, By Route of Administration
    4. Market Snapshot, By End User
    5. Market Snapshot, By Region
  4. Cancer Biological Therapy Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Biotech & immunotherapy advances
        2. Targeted therapy popularity growing
        3. More specialized cancer treatment centers
        4. Favorable biological therapy regulations
      2. Restraints
        1. Resistance to targeted treatments
        2. Reimbursement gaps for biological therapies
        3. Ethical issues with genetic manipulation
      3. Opportunities
        1. AI in drug research & development
        2. Precision medicine & personalized care focus
        3. Expansion into underserved markets
        4. Liquid biopsy for easier monitoring
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Cancer Biological Therapy Market, By Therapy Type, 2021 - 2031 (USD Million)
      1. Gene Therapy
      2. Monoclonal Antibody Therapy
      3. Vaccines Therapy
      4. Targeted Drug Therapy
      5. Bio chemotherapy
      6. Cancer Growth Blockers
      7. Others
    2. Cancer Biological Therapy Market, By Cancer Type, 2021 - 2031 (USD Million)
      1. Pancreatic Cancer
      2. Blood Cancer
      3. Lung Cancer
      4. Colorectal Cancer
      5. Others
    3. Cancer Biological Therapy Market, By Route of Administration, 2021 - 2031 (USD Million)

      1. Intravenous

      2. Subcutaneous

      3. Intrathecal

      4. Intramuscular

    4. Cancer Biological Therapy Market, By End User, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Specialty Clinics
      3. Cancer Research Centres
      4. Others
    5. Cancer Biological Therapy Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape Analysis
    1. Company Profiles
      1. F. Hoffmann-La Roche Ltd.
      2. Mylan N.V
      3. Teva Pharmaceutical Industries Ltd.
      4. Sanofi, Pfizer Inc.
      5. GSK plc
      6. Novartis AG
      7. Bayer AG
      8. Lilly
      9. Merck & Co., Inc.
      10. Sun Pharmaceutical Industries Ltd.
  7. Analyst Views
  8. Future Outlook of the Market